Published in Cancer on June 15, 2007
Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol (2011) 1.34
An audit of histopathology reports of carcinoma endometrium: experience from a tertiary referral center. J Postgrad Med (2015) 1.05
Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol (2012) 1.02
Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis. Ont Health Technol Assess Ser (2010) 0.90
The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma. Am J Surg Pathol (2013) 0.84
Controversies in surgical staging of endometrial cancer. Obstet Gynecol Int (2010) 0.81
Lymph node assessment in endometrial cancer: towards personalized medicine. Obstet Gynecol Int (2013) 0.77
Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer. Int J Gynecol Cancer (2015) 0.77
Survival advantage of lymphadenectomy in endometrial cancer. J Cancer Res Clin Oncol (2016) 0.76
Surgical management and postoperative treatment of endometrial carcinoma. Rev Obstet Gynecol (2008) 0.75
Role of lymphadenectomy in the staging of endometrial cancer. Nat Rev Clin Oncol (2009) 0.75
Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma. Gynecol Oncol (2017) 0.75
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol (2009) 5.59
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol (2005) 4.27
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2006) 3.39
Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet Gynecol (2013) 3.08
Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol (2011) 2.95
Down syndrome and Alzheimer disease: response to donepezil. Arch Neurol (2002) 2.82
A replication of the Autism Diagnostic Observation Schedule (ADOS) revised algorithms. J Am Acad Child Adolesc Psychiatry (2008) 2.82
Assessing missed opportunities for HIV testing in medical settings. J Gen Intern Med (2004) 2.72
Gene expression patterns in ovarian carcinomas. Mol Biol Cell (2003) 2.55
Robot-assisted radical prostatectomy: 5-year oncological and biochemical outcomes. J Urol (2012) 2.40
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2009) 2.32
Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol (2008) 2.11
Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol (2009) 2.08
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol (2004) 2.08
Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signaling pathway. J Immunol (2007) 2.04
Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer (2006) 1.92
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol (2013) 1.92
Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol (2013) 1.89
Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 1.88
Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol (2007) 1.82
Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success? J Clin Oncol (2008) 1.79
Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol (2008) 1.74
Validation of two instruments to assess technical bronchoscopic skill using virtual reality simulation. Respiration (2008) 1.72
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev (2009) 1.70
U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women? Obstet Gynecol (2016) 1.70
Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr (2005) 1.70
Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol (2007) 1.70
Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res (2012) 1.68
Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer. Gynecol Oncol (2005) 1.63
Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol (2007) 1.59
An alerting system improves adherence to follow-up recommendations from colonoscopy examinations. Gastroenterology (2011) 1.57
Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer (2008) 1.57
Hypothermic nerve-sparing radical prostatectomy: rationale, feasibility, and effect on early continence. Urology (2009) 1.54
Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol (2006) 1.52
Prevalence of ST131 among fluoroquinolone-resistant Escherichia coli obtained from rectal swabs before transrectal prostate biopsy. Urology (2013) 1.49
Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol (2007) 1.49
Preventing perioperative complications of robotic-assisted radical prostatectomy. Urology (2013) 1.48
Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Gynecol Oncol (2008) 1.47
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol (2010) 1.45
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol (2010) 1.43
Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol (2006) 1.42
To treat pelvic nodes or not: could the greater testicular scatter dose from whole pelvic fields confound results of prostate cancer trials? J Clin Oncol (2009) 1.38
Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer (2011) 1.37
In vivo optical coherence tomography for the diagnosis of oral malignancy. Lasers Surg Med (2004) 1.36
Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States. J Surg Oncol (2008) 1.36
Microvascular blood flow dynamics associated with photodynamic therapy, pulsed dye laser irradiation and combined regimens. Lasers Surg Med (2006) 1.35
Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys (2002) 1.34
Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol (2010) 1.31
Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol (2005) 1.31
Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer (2008) 1.30
In vivo multiphoton fluorescence imaging: a novel approach to oral malignancy. Lasers Surg Med (2004) 1.26
Management of melanomas of the female genital tract. Curr Opin Oncol (2008) 1.25
Placental site trophoblastic tumor: A study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol (2005) 1.24
Association between amygdala volume and anxiety level: magnetic resonance imaging (MRI) study in autistic children. J Child Neurol (2006) 1.24
Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol (2003) 1.24
Characteristics of success in mentoring and research productivity - a case-control study of academic centers. Gynecol Oncol (2012) 1.23
TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases. Cancer Res (2008) 1.23
Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected]. Clin Cancer Res (2008) 1.23
Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer (2004) 1.21
Impact of individual physicians on enrollment of patients into clinical trials. Am J Clin Oncol (2003) 1.21
In vivo diagnosis of oral dysplasia and malignancy using optical coherence tomography: preliminary studies in 50 patients. Lasers Surg Med (2009) 1.21
Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res (2006) 1.20
Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis. Gynecol Oncol (2005) 1.18
Detection and diagnosis of oral cancer by light-induced fluorescence. Lasers Surg Med (2003) 1.18
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol (2014) 1.18
Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol (2007) 1.18